FDA clears Elscint's TransACT protocol

October 25, 1995

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct inferior wall artifactscommon in myocardial imaging with thallium. The company is planningto adapt the technique for the adjustable-angle Varicam cameraas well.

Elscint also announced this month that it has received clearancefor its 2-tesla Prestige MRI scanner.